Immix Biopharma Inc. (IMMX)
NASDAQ: IMMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:53 AM ET
IMMX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $748.61M
- EPS (TTM)
- -$0.88
- Dividend yield
- None
- 52-week range
- 2.31 – 15.10
- Day range
- 8.96 – 9.37
- Volume / Avg
- 460.94K / 1.65M
- Beta
- —
- Shares outstanding
- 82.90M
- Next earnings
- Nov 6, 2026
52-week range
IMMX stock today
Shares of Immix Biopharma (IMMX) are trading lower on Oct 8 at $9.03, a drop of 4.85% or $0.46 per share, versus the S&P 500's 0.39% decline. Shares are 40.2% below their 52-week high of $15.10, set on Aug 25, 2026 and 290.9% above the 52-week low of $2.31, in the middle of the past year's range. IMMX is up 81.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 278.1%.
Immix Biopharma has posted a net loss over the last twelve months (EPS of -$0.88), so its P/E ratio is not meaningful. Immix Biopharma's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Immix Biopharma
Company profileImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ilya Rachman M.B.A., M.D., Ph.D.
- Headquarters
- Los Angeles, CA
- Employees
- 21
- IPO year
- 2021
- Website
- immixbio.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$24.30+169.10%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $-0.19
IMMX news
All IMMX newsImmix Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVBPArriVent BioPharma Inc. | 16.08 | -4.80% | $792.87M | vs IMMX |
| CRVSCorvus Pharmaceuticals Inc. | 9.84 | -5.48% | $827.75M | vs IMMX |
| ARDXArdelyx Inc. | 3.22 | -1.38% | $830.07M | vs IMMX |
| GERNGeron Corporation | 1.19 | -0.82% | $764.61M | vs IMMX |
| OBXObsidian Therapeutics Inc. | 12.33 | -6.63% | $761.35M | vs IMMX |
| LXRXLexicon Pharmaceuticals Inc. | 1.71 | -3.13% | $758.65M | vs IMMX |
| HELPHelus Pharma Inc. | 10.37 | -1.33% | $757.63M | vs IMMX |
| APMDApnimed Inc. | 18.14 | +0.55% | $755.18M | vs IMMX |
Indexes, lists and sector
Immix Biopharma stock FAQ
What is Immix Biopharma's stock price today?
IMMX last traded at $9.03 as of Oct 8, 11:53 AM EDT, down 4.85% on the day. Prices are delayed at least 15 minutes.
When is Immix Biopharma's next earnings date?
Immix Biopharma is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $-0.19.
Who is Immix Biopharma's CEO?
Dr. Ilya Rachman M.B.A., M.D., Ph.D. is the chief executive officer of Immix Biopharma Inc., which has about 21 employees.
What is the IMMX 52-week high?
The 52-week high for IMMX is $15.10 and the 52-week low is $2.31. The stock is currently 40.2% below its high.